As an obesity medicine physician scientist who regularly cares for patients with complex inflammatory conditions, this study reinforces what many of us have suspected clinically that the benefits of GLP-1 receptor agonists extend well beyond blood sugar control and weight loss and may fundamentally alter the disease trajectory for some of our highest-risk patients. Stanford, who was not involved in this research, is an obesity medicine physician scientist, educator and policy maker at Massachusetts General Hospital and Harvard Medical School, both in Boston
After 40 weeks, tirzepatide significantly outperformed placebo in both glycemic control and weight loss
The study populations with T2D The analyses on the associations of semaglutide with both incident and recurrent CUD among patients with T2D had a starting time of 12/2017 when semaglutide was approved in the US as Ozempic for treating T2D and an ending date of 5/2021 to allow us to separately examine the effects of semaglutide on CUD as Ozempic from those as Wegovy in the study population with obesity
Though this advantage is narrowing as oral GLP-1 formulations become available, including the GLP-1 six-in-one oral liquid and various tablet formulations like tirzepatide tablets , injection aversion remains a real barrier for many patients
To view or add a comment, sign in Keenova eyes Xiaflex as first drug for plantar fibromatosis: Ireland's Keenova is hoping that its Xiaflex therapy can become the first approved therapy for plantar fibromatosis, a debilitating condition affecting the feet
